Pure Global
NCT06378827

Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery

The Effect of Intraoperative Dexmedetomidine on Renal Function After Coronary Artery Bypass Graft Surgery
University of Novi Sad·Phase 2/3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
Dexmedetomidine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Novi Sad
Location
Novi Sad, Serbia
Timeline & enrollment
Phase
Phase 2/3
Start date
Apr 03, 2024
End date
Oct 01, 2024
Enrollment
100 participants
Primary outcome

Indicator of renal function,An early biomarker of kidney injury,The change of inflammatory markers

Summary

This is a prospective randomized clinical trial designed to determine the effect of
 intraoperative dexmedetomidine administration on renal function after coronary artery bypass
 graft surgery.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06378827
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06378827 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by University of Novi Sad and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.